Protagonist Therapeutics, Inc Revenue from Contract with Customer, Including Assessed Tax
Protagonist Therapeutics, Inc (PTGX) reported Revenue from Contract with Customer, Including Assessed Tax of $56.37 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-05-05
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $56.37M, a 99.03% increase year-over-year.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $7.44M, a 95.64% decline year-over-year.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $4.71M, a 0.79% increase year-over-year.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $5.55M, a 33.09% increase year-over-year.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for fiscal 2025 was $46.02M, a 89.41% decline from fiscal 2024.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for fiscal 2024 was $434.43M, a 624.05% increase from fiscal 2023.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for fiscal 2023 was $60.00M, a 125.73% increase from fiscal 2022.
- Protagonist Therapeutics, Inc revenue from contract with customer, including assessed tax for fiscal 2022 was $26.58M, a 2.84% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | $56.37M 10-Q · filed 2026-05-05 | $63.80M derived: sum of 2 quarters · filed 2026-05-05 | $68.52M derived: sum of 3 quarters · filed 2026-05-05 | $74.06M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $7.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.15M derived: sum of 2 quarters · filed 2026-02-25 | $17.70M derived: sum of 3 quarters · filed 2026-02-25 | $46.02M 10-K · filed 2026-02-25 |
| 2025-09-30 | $4.71M 10-Q · filed 2025-11-06 | $10.26M derived: sum of 2 quarters · filed 2025-11-06 | $38.58M 10-Q · filed 2025-11-06 | $209.22M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $5.55M 10-Q · filed 2025-08-06 | $33.87M 10-Q · filed 2025-08-06 | $204.50M derived: sum of 3 quarters · filed 2026-05-05 | $209.18M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $28.32M 10-Q · filed 2026-05-05 | $198.96M derived: sum of 2 quarters · filed 2026-05-05 | $203.63M derived: sum of 3 quarters · filed 2026-05-05 | $207.80M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $170.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $175.31M derived: sum of 2 quarters · filed 2026-02-25 | $179.48M derived: sum of 3 quarters · filed 2026-02-25 | $434.43M 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.67M 10-Q · filed 2025-11-06 | $8.84M derived: sum of 2 quarters · filed 2025-11-06 | $263.80M 10-Q · filed 2025-11-06 | $323.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $4.17M 10-Q · filed 2025-08-06 | $259.12M 10-Q · filed 2025-08-06 | $319.12M derived: sum of 3 quarters · filed 2026-02-25 | $319.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $254.95M 10-Q · filed 2025-05-06 | $314.95M derived: sum of 2 quarters · filed 2026-02-25 | $314.95M derived: sum of 3 quarters · filed 2026-02-25 | $314.95M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $60.00M derived: sum of 2 quarters · filed 2026-02-25 | $60.00M derived: sum of 3 quarters · filed 2026-02-25 | $60.00M 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | $0.00 derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | $859.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $859.00K derived: sum of 3 quarters · filed 2025-02-21 | $26.58M 10-K · filed 2025-02-21 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $859.00K derived: sum of 2 quarters · filed 2023-11-02 | $26.58M 10-Q · filed 2023-11-02 | $35.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $859.00K 10-Q · filed 2023-08-03 | $26.58M 10-Q · filed 2023-08-03 | $35.20M derived: sum of 3 quarters · filed 2024-02-27 | $45.48M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $25.72M 10-Q · filed 2023-05-04 | $34.34M derived: sum of 2 quarters · filed 2024-02-27 | $44.63M derived: sum of 3 quarters · filed 2024-02-27 | $46.89M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $8.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $18.90M derived: sum of 2 quarters · filed 2024-02-27 | $21.17M derived: sum of 3 quarters · filed 2024-02-27 | $27.36M 10-K · filed 2024-02-27 |
| 2021-09-30 | $10.29M 10-Q · filed 2022-11-08 | $12.55M derived: sum of 2 quarters · filed 2022-11-08 | $18.74M 10-Q · filed 2022-11-08 | $24.39M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $2.27M 10-Q · filed 2022-08-04 | $8.45M 10-Q · filed 2022-08-04 | $14.10M derived: sum of 3 quarters · filed 2023-03-15 | $27.22M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $6.19M 10-Q · filed 2022-05-05 | $11.84M derived: sum of 2 quarters · filed 2023-03-15 | $24.95M derived: sum of 3 quarters · filed 2023-03-15 | |
| 2020-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $18.76M derived: sum of 2 quarters · filed 2023-03-15 | $28.63M 10-K · filed 2023-03-15 | |
| 2020-09-30 | $13.11M 10-Q · filed 2021-11-03 | $22.98M 10-Q · filed 2021-11-03 | ||
| 2019-12-31 | $2.72M 10-K · filed 2020-03-10 | $6.86M derived: sum of 2 quarters · filed 2020-03-10 | $231.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $4.14M 10-K · filed 2020-03-10 | |||
| 2019-03-31 | $1.56M 10-K · filed 2020-03-10 | $3.91M derived: sum of 2 quarters · filed 2020-03-10 | $10.03M derived: sum of 3 quarters · filed 2020-03-10 | $21.70M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-12-31 | $2.35M 10-K · filed 2020-03-10 | $8.47M derived: sum of 2 quarters · filed 2020-03-10 | $20.14M derived: sum of 3 quarters · filed 2020-03-10 | $30.93M 10-K · filed 2019-03-12 |
| 2018-09-30 | $6.12M 10-K · filed 2020-03-10 | $17.79M derived: sum of 2 quarters · filed 2020-03-10 | $28.57M 10-Q · filed 2018-11-06 | $39.85M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $11.67M 10-K · filed 2020-03-10 | $22.45M derived: sum of 2 quarters · filed 2020-03-10 | $33.74M derived: sum of 3 quarters · filed 2020-03-10 | $42.52M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $10.78M 10-K · filed 2020-03-10 | $22.06M derived: sum of 2 quarters · filed 2020-03-10 | $30.84M derived: sum of 3 quarters · filed 2020-03-10 | |
| 2017-12-31 | $11.28M 10-K · filed 2019-03-12 | $20.06M derived: sum of 2 quarters · filed 2019-03-12 | $20.06M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $8.78M 10-K · filed 2019-03-12 | $8.78M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |